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Genomic characterisation of clinical and
environmental Pseudomonas putida group
strains and determination of their role in
the transfer of antimicrobial resistance
genes to Pseudomonas aeruginosa
Silke Peter1,2* , Philipp Oberhettinger1,2, Leonard Schuele1,2,7, Ariane Dinkelacker1,2, Wichard Vogel4,
Daniela Dörfel4,5, Daniela Bezdan3,6,8,9, Stephan Ossowski3,6,10, Matthias Marschal1,2, Jan Liese1,2
and Matthias Willmann1,2
Abstract
Background: Pseudomonas putida is a Gram-negative, non-fermenting bacterium frequently encountered in various
environmental niches. P. putida rarely causes disease in humans, though serious infections and outbreaks have
been reported from time to time. Some have suggested that P. putida functions as an exchange platform for
antibiotic resistance genes (ARG), and thus represents a serious concern in the spread of ARGs to more pathogenic
organisms within a hospital. Though poorly understood, the frequency of ARG exchange between P. putida and the
more virulent Pseudomonas aeruginosa and its clinical relevance are particularly important for designing efficient
infection control strategies, such as deciding whether high-risk patients colonized with a multidrug resistant but
typically low pathogenic P. putida strain should be contact isolated or not.
Results: In this study, 21,373 screening samples (stool, rectal and throat swab) were examined to determine the
presence of P. putida in a high-risk group of haemato-oncology patients during a 28-month period. A total of 89 P. putida
group strains were isolated from 85 patients, with 41 of 89 (46.1%) strains harbouring the metallo-beta-lactamase gene
blaVIM. These 41 clinical isolates, plus 18 blaVIM positive environmental P. putida isolates, and 17 blaVIM positive P.
aeruginosa isolates, were characterized by whole genome sequencing (WGS).
We constructed a maximum-likelihood tree to separate the 59 blaVIM positive P. putida group strains into eight distinct
phylogenetic clusters. BlaVIM-1 was present in 6 clusters while blaVIM-2 was detected in 4 clusters. Five P. putida group
strains contained both, blaVIM-1 and blaVIM-2 genes.
In contrast, all P. aeruginosa strains belonged to a single genetic cluster and contained the same ARGs. Apart from
blaVIM-2 and sul genes, no other ARGs were shared between P. aeruginosa and P. putida. Furthermore, the blaVIM-2 gene
in P. aeruginosa was predicted to be only chromosomally located.
(Continued on next page)
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Conclusion: These data provide evidence that no exchange of comprehensive ARG harbouring mobile genetic
elements had occurred between P. aeruginosa and P. putida group strains during the study period, thus eliminating the
need to implement enhanced infection control measures for high-risk patients colonized with a blaVIM positiv P. putida
group strains in our clinical setting.
Keywords: Pseudomonas putida, VIM, Horizontal gene transfer
Background
Pseudomonas putida is a Gram-negative, rod-shaped,
non-fermenting bacterium that is ubiquitously encoun-
tered in the environment. It harbours a broad spectrum
of metabolic enzymes, allowing the species to adapt to
various niches, including soil and water-associated habi-
tats [1]. P. putida is a rare cause of infection in humans.
However, there are several reports of bacteraemia,
wound and eye infections, urinary tract infection, pneu-
monia, central venous catheter infection and soft tissue
infections caused by P. putida [2–9]. A high proportion
of P. putida bacteraemia is considered to be catheter-re-
lated, occurring predominantly in immunocompromised
hosts and generally associated with a low rate of mortality
[2, 10, 11]. However, lethal cases of bacteraemia and soft
skin tissue infections have been described [3, 4]. While the
antimicrobial resistance patterns of clinical isolates varied
between studies, multidrug-resistant P. putida isolates har-
bouring metallo-β-lactamase (MBL) genes have been
reported from all over the world [6–9, 12–19]. MBLs belong
to the molecular class B β-lactamases and are characterized
by requiring zinc for the catalysis of β-lactams [20]. MBLs
can confer resistance to clinically important β-lactams
including carbapenems which are often considered as last
line of defence in critically ill patients. Aggravating the treat-
ment limitation, the most important enzymes of this group,
Verona integron-encoded metallo-β-lactamase (VIM),
Imipenemase (IMP), and New Delhi metallo-β-lactamase
(NDM), are often co-localized with other resistance confer-
ring genes on mobile genetic elements in P. aeruginosa [21].
Several outbreaks of P. putida occurred on ICU (intensive
care units) as well as non-ICU wards, some of which were
related to the transmission of contaminated fluids [22–25].
This underlines the ability of P. putida not only to colonize
patients, but also to persist in fluids and in water-associated
hospital environments [13]. The role of environmental bac-
teria like Pseudomonas species behaving as reservoirs and
vectors of resistance determinants in hospital water systems
has become a serious concern to infection control profes-
sionals. Investigations into bacteria isolated from hospital
wastewater detected blaVIM MBL genes in various bacterial
species [26]. It was suggested that P. putida functions as an
exchange platform for genetic elements between environ-
mental and clinical strains. This was evident in the analysis
of a P. putida carbapenem resistance-conferring conjugative
plasmid, which contained genetic regions of both clinical
and environmental microbiota [27]. Additionally, the
characterization of genetic resistance elements of eight
P. putida and eleven P. aeruginosa clinical isolates sug-
gested horizontal dissemination of blaVIM-2 in a subset
of strains [28]. However, the detailed mechanisms,
frequency of antimicrobial resistance exchange and
relevance between P. putida and P. aeruginosa remain
poorly understood.
Following an outbreak of multidrug-resistant P. aeruginosa
strains, weekly active screening cultures (ASC) were
introduced for the detection of Pseudomonas species at
the haemato-oncology wards in our hospital [29]. Interest-
ingly, P. putida was frequently recovered during ASC be-
sides P. aeruginosa. In one case, a blaVIM positive P. putida
and a blaVIM positive P. aeruginosa strain were isolated from
a single stool sample, suggesting that the transfer of ARGs
might have occurred between the two species in the patient.
The dissemination of multidrug resistance elements to suc-
cessful P. aeruginosa clones represents a serious health care
concern [28]. This scenario, in combination with the fact
that blaVIM positive P. aeruginosa strains were continuously
isolated in our patients made it difficult to establish infection
control strategies for patients colonized with blaVIM positive
P. putida. Systematically gathered data were not available to
help us form the basis for a recommendation, a point that
encouraged us to conduct this study.
In order to characterize the role of P. putida group
strains in transmitting determinants of antimicrobial resist-
ance to P. aeruginosa within the patient and the patient-
related environment, an observational study was conducted
over a 28-month period. Our aim was to evaluate i) the
frequency of colonisation with P. putida in a high-risk
haemato-oncological population, ii) the antimicrobial sus-
ceptibility patterns, iii) the genetic relatedness of P. putida
and P. aeruginosa strains and iv) to compare genetic anti-
biotic resistance elements from P. putida and P. aeruginosa
strains isolated from the same patient cohort and environ-
ment during the study period.
Methods
Strains included in the study
A total of 21,373 screening samples obtained from a
high-risk group of hemato-oncology patients were exam-
ined over a study period of 28 months. The samples
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were obtained as part of routine care. To address the
study objectives, we included the following isolates: i)
the first P. putida isolate per patient, ii) all blaVIM posi-
tive P. aeruginosa isolates recovered from the same
patient cohort during the study period and iii) all blaVIM
positive P. putida and P. aeruginosa recovered from patient-
associated environmental sources. The detailed workflow of
the study is depicted in Additional file 1: Figure S1.
Culture, identification and drug-susceptibility testing of
bacterial strains
Screening cultures (throat swabs, rectal swabs and stool sam-
ples) were examined for the presence of Pseudomonas sp. by
plating the specimens on Cetrimide agar (Becton, Dickinson
and Company, France) and incubation for 48 h, at 35 °C.
Bacterial identification was achieved using a linear Matrix-
assisted laser desorption ionization-time of flight (MALDI-
TOF) mass spectrometer (AXIMA Assurance, bioMérieux
SA, France) and confirmed by MALDI-TOF mass spectrom-
etry (Microflex LT, Bruker Daltonics, Germany). Isolates be-
longing to the P. putida group (P. putida, P. monteilii, P.
plecoglossicida, P. mosselii, P. fulva, P. parafulva, P. cremorico-
lorata) and P. aeruginosa isolates were included in the study
[30]. Strains from the P. putida group are referred to as “P.
putida” in our study. In vitro antimicrobial susceptibility test-
ing was performed with the VITEK 2 system (bioMérieux
SA, France) and confirmed by Etest (bioMérieux SA, France)
for meropenem. Results were interpreted according to the
guidelines of the European Committee on Antimicrobial
Susceptibility Testing (EUCAST), applying the clinical break-
points for P. aeruginosa [31]. The first strain isolated from a
patient was included in the study. P. putida strains from the
same patient were additionally included if they differed in the
antimicrobial susceptibility pattern by more than two anti-
biotic classes. Environmental isolates were obtained from
water-associated sources (toilet, shower and basin sink) in the
patients’ rooms. Sampling was performed at four different
time points during the study (month 3, 8, 24, 28). Swabs were
taken at a defined location and processed as described above.
The molecular detection of the metallo-β-lactamase genes
blaIMP and blaVIM was performed in all meropenem-non-
susceptible isolates as described previously [32]. All strains
were stored at −80 °C for further analysis.
DNA extraction, library preparation, whole genome
sequencing (WGS)
Genomic DNA was extracted from overnight bacterial cul-
tures using the UltraClean® Microbial DNA isolation kit
(MO BIO Laboratories Inc., Carlsbad, USA). Genomic DNA
was sheared by Covaris M220 (Covaris, Woburn, USA) to
obtain 550 bp fragments. DNA libraries were prepared with
TruSeqNano DNA LT Kit (Illumina, San Diego, USA) using
the standard protocol. Barcoded libraries were analyzed
on the QIAxcel Advanced Instrument (Qiagen, Hilden,
Germany). All libraries were sequenced at 2 × 250 bp
on an Illumina MiSeq (Illumina, San Diego, USA), with
the exception of two isolates (P21-B and P21_aerugi-
nosa) in which DNA was extracted using the Qiagen
Genomic-tip 100/G kit (Qiagen, Hilden, Germany) and
sequencing was performed generating 2 × 300 bp
paired-end reads and isolate P. aeruginosa P6 which
was sequenced generating 2 × 50 bp on an Illumina
HiSeq2000 (Illumina, San Diego, USA).
WGS data analysis
Sequencing reads were assembled using the A5 pipeline
(version 20,140,604) and SPAdes (version 3.7.0) [33, 34]. The
core genomes of P. putida and P. aeruginosa were generated
by Spine (version 0.1.2) using the default parameter setting
except in adjusting segment length to 1000 bp resulting in a
P. putida core genome of 2,068,252 bp and a P. aeruginosa
core genome of 6,193,571 bp. Core genome SNPs were called
using SPANDx (version 3.1) [35]. A maximum-likelihood tree
was then estimated using RAxML (version 8.2.6) with a GTR
substitution model and gamma distribution of rates undergo-
ing 1000 bootstraps [36]. The final tree was visualized by
FigTree (version 1.4.2).
The average nucleotide identity between assembled
strains of the P. putida group was calculated using JSpecies
(version 1.2.1) [37]. Whole genome sequence data of type
strains from the P. putida group and closely related species
[38] were obtained from the NCBI database: P. putida
NBRC 14164 (NC_021505.1), P. monteilii NBRC
103158 = DSM 14164 (NZ_JHYV00000000.1), P. parafulva
NBRC 16636 =DSM (GCA_000730645.1), P. fulva NBRC
16637 = DSM 17717 (NZ_JHYU00000000.1), P. plecoglossi-
cida NBRC 103162 =DSM 15088 (NZ_JHYX00000000.1),
P. taiwanensis DSM 21245 (NZ_AUEC00000000.1), P. mos-
selii DSM 17497 (NZ_JHYW00000000.1), P. entomophila
str. L48 (NC_008027.1), P. japonica NBRC 103040 = DSM
22348 (NZ_BBIR00000000.1), P. vranovensis DSM 16006
(NZ_AUED00000000.1), P. alkylphenolia strain KL28
(NZ_CP009048.1, P. cremoricolorata DSM 17059 = NBRC
16634 (NZ_CP009455.1).
WGS datasets were analysed for the presence of acquired
resistance genes by uploading the assembled genomes to
the ResFinder 2.1 web-based analysis tool [39]. Due to
errors in the genome assembly, resistance genes might be
missed by this approach. Therefore, detected resistance
genes were confirmed by re-mapping the quality trimmed
reads against any resistance gene identified in the assem-
blies of the study strains using BWA-MEM [40] with a
minimal mapping score of 40. The presence of plasmids
was predicted from the WGS datasets, applying the web-
based tool PlasmidFinder [41], Recycler [42] and plasmid-
SPAdes (version 3.9.0) [43]. Predicted plasmids (>2000 bp)
were examined for ARGs by applying the ResFinder 2.1
web-based analysis tool. The genetic environment of the
Peter et al. BMC Genomics  (2017) 18:859 Page 3 of 11
blaVIM gene was examined in all contigs harbouring blaVIM
that originated from the WGS datasets and the predicted
plasmids if blaVIM was present. Therefore, the contigs ori-
ginating from the a5 assembly were annotated using
PATRIC [44], followed by a manual examination of 10 kbp
upstream and downstream of the blaVIM gene to identify
neighbouring ARGs, integrons, plasmid-specific genes or
transposon-related genes. Due to the limitations of the as-
sembly in eleven P. putida strains and five P. aeruginosa
strains, no blaVIM could be identified from the FASTA files
assembled with a5. In addition, the blaVIM gene was located
on contigs smaller than 10 kb in another eleven P. putida
strains. In these cases, the FASTA generated by SPAdes
was used for the analysis of the genetic environment of the
blaVIM gene and for the determination of plasmidspecific or
transposon-related genes. This information and assembly
quality scores are summarized in Additional file 2: Table S1
and Additional file 3: Table S2.
The genomic localization of the blaVIM gene was
determined as follows: a localisation on a plasmid was
considered most likely, if one of the bioinformatic plas-
mid detection tools (PlasmidFinder, Recycler or plasmid-
SPAdes) predicted a blaVIM harbouring contig to be a
plasmid. If the respective contig was not predicted to be
a plasmid and if no plasmid-specific genes were identi-
fied on the contig harbouring blaVIM, the location of the
blaVIM gene was considered chromosomal. In case the
blaVIM harbouring contig was not predicted to be a plas-
mid but plasmid-specific genes were observed within the
nucleotide range described above, the localisation of the
blaVIM gene was considered indeterminate.
Construction of the 16S rRNA based maximum-likelihood
tree
In order to further investigate whether the core genome
clustering of the P. putida group strains was based on
their affiliation to the different species of this group, we
extracted the 16S rRNA sequences from each assembly
and generated an clustalW alignment [45] after integra-
tion of reference sequences (P. putida AB008001, P.
fulva AB060131, P. parafulva AB060133, P. plecoglossi-
cida AB 009457, P. mosselii AF072688, P. alkylphenolica
AY324319, P. vranovensis AY970951, P. cremoricolorata
AB060137, P. japonica AB126621, P. entomophila
AB541974, P. taiwanensis EU857417, P. monteilii
AB211409) from the SILVA database (https://www.arb-
silva.de/). The 16S rRNA maximum-likelihood tree was
generated using RAxML (version 8.2.6) with a GTR sub-
stitution model and gamma distribution of rates under-
going 1000 bootstraps [36].
Epidemiological data
Epidemiological data were obtained to detect potential
transmissions between patients that were colonized with
strains from the same genetic clusters or to localize a
potential environmental source. A Time-Place-Sequence
algorithm characterized transmission likelihood as de-
scribed previously with minor modifications [29]. The
probability of transmission from patient 1 to patient 2
was based on three criteria. Criterion 1 was considered
fulfilled if the patients were hospitalized on the same
ward for at least 24 h (possible transmission); criterion 2
was considered fulfilled if patient 2 stayed in the same
room up to 3 months (probable transmission) or more
than 3 months (possible transmission) after the first pa-
tient. Criterion 3 was fulfilled when both patients shared
the same room at the same time with an overlap of at
least 24 h (probable transmission). For identification of a
potential environmental source, the rooms, wards and
transfers during the hospital stay were documented for
patients colonized with a blaVIM positive P. putida strain.
Results
Rectal swabs, throat swabs and stool samples were obtained
from a weekly active screening culture program to detect
Pseudomonas sp. colonization. A total of 21,373 specimens
including 10,528 rectal swabs, 8904 throat swabs and 1941
stool samples from 2276 patients were analysed over a period
of 28 months. In total, 89 P. putida strains were isolated from
85 patients and were further characterized. These strains orig-
inated from rectal swabs (n = 46), throat swabs (n = 26), and
stool samples (n = 17). The resistance characteristics of the P.
putida strains investigated are summarized in Table 1. High-
est resistance rates were observed for piperacillin (68.5%),
piperacillin-tazobactam (66.3%), followed by meropenem
(64.1%), ceftazidime (57.3%), ciprofloxacin (47.2%), cefepime
(43.8%) and gentamicin (14.6%). A blaVIM gene was detected
in 41 of the 62 meropenem-non-susceptible strains (66.1%).
These 41 strains were isolated from 40 patients. The majority
of blaVIM positive isolates were resistant to cefepime (92.2%)
in contrast to blaVIM negative isolates with a susceptibility rate
of 97.9%. The blaVIM positive isolates were generally resistant
to most antibiotics, with the exception of gentamicin, to
which 28 of 41 isolates (68.3%) were susceptible, suggesting
the presence of at least two genetically different blaVIM posi-
tive P. putida strains.
Genetic relatedness of blaVIM positive P. putida strains
In order to characterize genetic relatedness, whole genome
sequencing of the 41 blaVIM positive patient isolates and 18
blaVIM positive environmental isolates was performed. The
maximum-likelihood tree showed a separation into 8 dis-
tinct clusters (Fig. 1a). Cluster 4 comprised most strains
(n = 20), followed by cluster 5 (n = 14), cluster 7 (n = 11)
and cluster 6 (n = 7). The other four clusters contained only
one or two isolates. In order to increase the resolution of
the closely related strains in clusters 4, 5, 6, and 7, a separ-
ate maximum likelihood phylogeny was constructed with
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those strains. Thereby, clusters 4, 5 and 6 could be further
divided into subclusters (Fig. 1b). Interestingly, clusters 5 and
7 predominantly contained isolates originating from patients,
whereas clusters 4 and 6 comprised both isolates from
patients and the environment. In order to assess whether the
different phylogenetic clusters represent the different species
of the P. putida group, the average nucleotide identity of the
study isolates and closely related type strains was performed
(Additional file 4: Table S3 and Additional file 5: Table S4).
With the exception of cluster 1, 7, 8 which were related to P.
monteilii, none of the clusters showed ANI values >95% with
any of the reference type strain genomes (Additional file 5:
Table S4). Additionally, the WGS based maximum-likelihood
phylogeny was compared to a 16S rRNA based maximum-
likelihood phylogeny tree including 16S rRNA reference
strain sequences (Additional file 6: Figure S2). The strains of
the WGS clusters 2, 3, 4, 5 and 6 arranged in an equal man-
ner. While the clusters 1, 8 and three strains of cluster 7
could not be further resolved based on the 16S RNA
maximum-likelihood phylogeny, they closely clustered with
the P. monteilii reference, thus confirming the observations of
the ANI analysis.
Timeline of colonization and transmission routes
BlaVIM positive P. putida strains from different phylo-
genetic clusters were encountered continuously in the
40 colonized patients over the 28 months as displayed in
Fig. 2. There was no accumulation of a certain genetic
cluster observed at a given point in time.
In order to establish transmission routes, epidemio-
logical data were linked to patients and environmental
samples within the same genetic cluster. This enabled us
to detect 12 cases of probable transmissions (summarized
in Additional file 7: Table S5). According to our analysis,
plausible routes of transmission include the following: i)
Patient colonization following exposure to an environ-
mental source was considered probable if environmental
isolates that belonged to the same phylogenetic cluster as
the isolate of the patient were recovered before the patient
stayed in the room (e.g. cluster 4B, P5). ii) Patient-to-
patient transmission was considered probable when the
patients stayed in the same room at the same time (e.g.
cluster 7 P28/29) and when both patients were sequen-
tially colonized with P. putida isolates from the same
phylogenetic cluster. For patients that stayed on the same
ward at the same time or consecutively in the same room,
a transmission from an environmental source was consid-
ered possible. In all cases, transmissions via hospital
personnel could be another route and cannot be excluded.
Genetic relatedness of P. aeruginosa blaVIM positive
strains isolated from the study cohort and environment
sources
During the study period, blaVIM positive P. aeruginosa
strains were isolated from seven patients of the study
cohort. The strains were further characterized in order
to determine their resistance gene content and to evalu-
ate whether genetic resistance determinants were shared
between P. putida and P. aeruginosa strains isolated
from the same patient cohort and environmental
sources. All seven blaVIM positive P. aeruginosa isolates
were resistant to gentamicin, piperacillin, piperacillin-
tazobactam, ceftazidime, cefepime, meropenem and cip-
rofloxacin. All strains remained susceptible to colistin.
In addition, 10 blaVIM positive P. aeruginosa environmen-
tal isolates were included in the study. In contrast to the
genetic diversity observed in P. putida isolates, all patient
and environmental blaVIM positive P. aeruginosa strains were
genetically highly similar as illustrated in the maximum-
likelihood phylogenetic tree in Additional file 8: Figure S3.
Characterization of antibiotic resistance genes in blaVIM
positive P. putida and P. aeruginosa isolates
The presence of ARGs was explored in all isolates in order
to assess ARG transfer between P. putida and P. aeruginosa
blaVIM positive isolates. The presence and absence of ARGs
Table 1 Susceptibility profiles of 89 clinical isolates belonging to the P. putida group. Strains were isolated from throat swabs
(n = 26), rectal swabs (n = 46) and stool (n = 17) active screening cultures from 85 patients over period of 28 months
Antimicrobial agent blavim negative (n = 48)
n(%)
blavim positive (n = 41)
n(%)
Totla (n = 89)
n (%)
R I S R I S R I S
PIP 20 (41.7) – 28 (58.3) 41 (100) – 61 (68.5) – 28 (31.5)
TZP 18 (37.5) – 30 (62.5) 41 (100) – 59 (66.3) – 30 (33.7)
CAZ 10 (20.8) – 38 (79.2) 41 (100) – 51 (57.3) – 38 (42.7)
FEP 1 (2.1) – 47 (97.9) 38 (92.2) – 3 (7.8) 39 (43.8) – 50 (56.2)
MEM 16 (33.3) 5 (10.4) 27 (56.3) 41 (100) 57 (64.1) 5 (5.6) 27 (30.3)
CIP 2 (4.2) 3 (6.3) 43 (89.5) 40 (97.6) 1 (2.4) 42 (47.2) 4 (4.5) 43 (48.3)
GEN 0 (0) – 48 (100) 13 (31.7) – 28 (68.3) 13 (14.6) – 76 (85.4)
PIP piperacillin, TZP piperacillin-tazobactam, CAZ ceftazidime, FEP cefepime, MEM meropenem, CIP ciprofloxacin, GEN gentamicin, S susceptible, I intermediate,
R resistant
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is shown in Fig. 3. All P. putida strains from a phylogenetic
cluster harboured the same ARGs with the exceptions of
cluster 4B and cluster 5A, where different ARG patterns
were observed.
The blaVIM-1 gene was present in 7 phylogenetic clus-
ters and subclusters (2, 3, 4A, 4B, 5A, 6B and 8) while
the blaVIM-2 gene was detected in 6 phylogenetic clusters
and subclusters (1, 5A, 5B, 6A, 6C and 7). Of note, five
Fig. 1 a Core genome maximum-likelihood phylogeny of blaVIM positive P. putida isolates comprising 41 blaVIM positive patient isolates (“P” as first letter) and
18 blaVIM positive environmental isolates (“E” as first letter). The strains could be divided into 8 different phylogenetic clusters. The numbers displayed at the
nodes are bootstrap values. The scale bar represents the expected number of changes per site. b For each of the clusters 4-7, a separate core genome
maximum-likelihood tree was constructed and allowed further resolution into subclusters. An outgroup strain (P34 from cluster 1) was introduced into cluster
7 to ensure a proper visualisation of the high similarity between the cluster members
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strains in cluster 5A contained both, blaVIM-1 and bla-
VIM-2 genes (P3, P19, P24, P26, P39). In the VIM-1
groups, the blaVIM-1 gene was often co-localized with
aminoglycosides resistance genes and was either pre-
dicted to be on a plasmid (clusters 2, 4A, 4B, 6B and 8)
or on the chromosome (clusters 3 and 5A) (Add-
itional file 9: Table S6). The blaVIM-2 gene was also often
co-localized with aminoglycoside ARGs, but was only
predicted to be located on a plasmid in one strain (P4)
of cluster 7 (Additional file 9: Table S6).
In contrast to the diverse ARG situation in the P.
putida isolates, all 17 P. aeruginosa isolates harboured
the beta-lactamases blaVIM-2, blaPAO, blaOXA-4, blaOXA-
50 in addition to aminoglycoside resistance enzymes
(aph(3′)-IIb, aac(3)-Id and aadA2) and other ARG
groups (sul1, cmlA1, catB7, dfr5, tet(G) and fosA). The
blaVIM-2 was either directly flanked by the ARGs dfrB5
and aac(3)-Id or was located alone with no adjacent
ARGs in the direct genetic environment. No plasmid-
specific genes were detected 10 kb upstream and down-
stream from the blaVIM-2 location on the respective
contig. Furthermore, no blaVIM-2 harbouring plasmids
were predicted by PlasmidFinder, Recycler and plasmid-
SPAdes (Additional file 9: Table S6), which provides
evidence for a chromosomal location of blaVIM-2 in
those strains. Furthermore, despite sharing the blaVIM-2
and sul gene, no other resistance genes were shared
between P. aeruginosa and P. putida strains. Both
findings clearly reflect the absence of epidemiological
evidence for the exchange of genetic elements har-
bouring ARG between P. aeruginosa and P. putida.
Interestingly, study patient 21 was colonized with a
P. putida isolate (P21A, cluster 7) prior to the
simultaneous isolation of a P. putida strain (P21B,
cluster 3) and P. aeruginosa strain P21 from the same
stool specimen. Apart from blaVIM-2 (P21A) and sul
(P21B), both P. putida strains shared no further com-
mon ARGs with the P. aeruginosa strain. Thus, our
initial suspicions, based only on epidemiological data,
that an exchange of comprehensive genetic mobile
elements and horizontal spread of blaVIM had
occurred, were clearly disproven.
Discussion
Infections and colonization with P. putida have been
reported from various sources [2–9]; however, to the best
of our knowledge, the study presented here is the first to
systematically evaluate the frequency of P. putida
colonization in a haemato-oncological patient population
combined with a comprehensive genetic characterization of
the isolates. During the 28-month study period, active
screening cultures that included 2276 patients were per-
formed and resulted in the isolation of 89 P. putida strains
from 85 patients. Among these isolates, the rate of blaVIM
positive P. putida was very high (46.1%). This is particularly
worrisome as blaVIM positive low pathogenic bacteria may
transfer the blaVIM gene to more pathogenic bacteria in a
colonized patient, thereby increasing the risk to an
Fig. 2 Timeline of blaVIM positive P. putida colonization in 40 patients during the study period. The different phylogenetic clusters for patients P1-P40 are
displayed. The major clusters were continuously observed during the study period, without accumulation of a certain cluster at a given point in time. In
P21, two P. putida strains and one P. aeruginosa strain were isolated (P21A, cluster 7 and P21B cluster 3 and P. aeruginosa P21 Additional file 8: Figure S3)
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individual patient of becoming infected with a modified
strain that is both resistant and highly pathogenic. These
modified strains could then be spread in the hospital envir-
onment and could build up a reservoir that constitutes a
continuous exposure to patients. Moreover, such strains
could become the source strains for a further blaVIM gene
transfer to other bacterial species in patient-related hospital
environments, potentially causing a chain reaction that may
be impossible to control once in progress.
Several studies have provided evidence for the transfer
of ARGs from P. putida to P. aeruginosa and have de-
scribed the role of P. putida as a reservoir and exchange
platform for ARGs [12, 18, 28]. If these findings were
proven true, we would then need to target P. putida as
well as the more pathogenic P. aeruginosa in a high-risk
patient setting by using appropriate infection control
measures. Lee et al. examined 43 blaVIM-2 positive P. aeru-
ginosa and 9 blaVIM-2 positive P. putida clinical isolates.
The flanking regions of one P. aeruginosa isolate and one
P. putida isolate were sequenced revealing two different
integron structures. Applying the filter mapping method,
carbapenem resistance could be successfully transferred
from 6 of the P. aeruginosa isolates and 2 of the P. putida
isolates to a P. aeruginosa recipient. However, no plasmid
harbouring the blaVIM-2 gene could be detected in the re-
cipient strain [18]. Juan et al. examined 8 P. putida and 11
P. aeruginosa clinical isolates from one hospital [28]. Both
P. putida and P. aeruginosa isolates possessed an identical
transposon that contained a blaVIM-2 integron, thus provid-
ing evidence for a horizontal gene transfer between the two
species. In addition, plasmids harbouring blaVIM-2 from
three P. putida clones were successfully transferred to the
laboratory P. aeruginosa strain PAO1. Nevertheless, the
blaVIM-2 genes in the clinical P. aeruginosa strains had a
chromosomal location in all but one clone. Juan et al. sug-
gested the concurrent presence of the blaVIM-2 gene on the
chromosome in that particular P. aeruginosa strain. But it
must be noted that the plasmid harbouring blaVIM-2 dif-
fered in its genetic pattern from the plasmid harbouring
blaVIM-2 of the P. putida isolates [28]. Therefore, the data
present epidemiological evidence for the horizontal gene
transfer of a transposon structure containing blaVIM-2, but
no evidence for the transfer of a complete identical plasmid
between the species [28]. In another study, also conducted
Fig. 3 Overview of ARG content in the phylogenetic clusters of blaVIM positive P. putida and P. aeruginosa strains. Strains within a cluster usually contained
the same ARGs, with the exception of clusters 4B and 5A as indicated by the shaded fields. In cluster 4B both genes, aph(3′)-XV and aacA4 were present in
P5, P8, P11, E1, E3, E5, E11, E13 (Cluster 4B I). Aph(3′)-XV was missing in the isolates P13, P38, P40, E10, E12, E14 (cluster 4B II), and aacA4 was missing in the
isolates P9, P25, P40, E16 and E22 (cluster 4B III). In P40 both genes were absent (cluster 4B IV). In cluster 5A, two different types of ARG patterns were
observed. Here, the strains P3, P19, P24, P26, P39 (cluster 5A II) contained a blaVIM-2, aadA1 and aph3-Ib gene in addition to the other ARGs of that cluster
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on the Canary Islands, six MBL-producing strains were
examined, including two blaIMP-15 positive P. aeruginosa
and two blaIMP-15 positive P. putida isolates. The simultan-
eous merging of the two species harbouring the rarely
encountered blaIMP-15 gene suggested a horizontal gene
transfer, but the location of the genes was chromosomal
and plasmid transfer experiments did not result in resistant
recipients [12].
In the study presented here, P. putida strains from our
hospital formed a heterogeneous group comprising eight
phylogenetic clusters. Interestingly, the main clusters
were distributed over the whole study period (Fig. 2),
without an accumulation of a certain cluster at a given
point in time. Transmission analysis revealed that
environment-to-patient transmission as well as patient-
to-patient transmission was likely to have occurred,
which is quite similar to the transmission routes observed
during a P. aeruginosa outbreak in our hospital [29].
A total of 11 different ARGs were detected in our P. putida
strains (Fig. 3). Strains of the same phylogenetic cluster usu-
ally contained the same ARGs, indicating a clonal spread
rather than horizontal gene transfer of ARGs. Exceptions to
this were found in clusters 4B and 5A where strains differed
in their ARG content. This suggests that strains in these clus-
ters acquired resistance genes via gene transfer at some point.
Of particular note is what we found in cluster 5A, in which
five isolates harboured both a blaVIM-1 and a blaVIM-2 gene
(Fig. 3, Cluster 5A II). However, there was no evidence for
the presence of ARGs on plasmids in the strains of this clus-
ter. But plasmids were identified in strains belonging to other
clusters. Plasmids carrying blaVIM-1 were predicted in
24 P. putida from five phylogenetic clusters and a plas-
mid carrying blaVIM-2 in one strain from cluster 7. Since
the blaVIM-2 gene was also detected in our P. aeruginosa
strains, we hypothesized that an ARG transfer might have
occurred between both species. But despite the detection of
the plasmid harbouring blaVIM-2 in one P. putida, we could
not detect any further shared ARGs between both species
besides the blaVIM-2 and sul genes. No plasmids harbouring
blaVIM-2 were predicted in P. aeruginosa isolates.
To date, there are both limitations and challenges in ap-
plying WGS to analyse ARGs and predict plasmids. First,
the quality of assembly is a crucial factor for a general ana-
lysis of ARGs and for the analysis of the genomic environ-
ment. ARGs that are incomplete or incorrectly assembled
might not be found in applying tools based on searches
against ARG databases (e.g. ResFinder). In order to
minimize this limitation, two different assemblers were
applied and both assemblies searched for the presence of
ARGs. The presence of identified ARGs was subsequently
confirmed by remapping the unassembled reads against
these ARGs. Another limitation is that the location of a
certain ARG (i.e. on a chromosome or plasmid) can only
be predicted. The ability to identify a plasmid depends on
several factors like genome coverage, read length and
presence of repetitive sequences on the plasmid [46]. Due
to these limitations, we applied three different bioinfor-
matics tools (PlasmidFinder, plasmidSPAdes and recycler)
to our dataset in order to augment plasmid detection [41–
43]. Furthermore, plasmids predicted using these tools
were only interpreted in combination with a manual
search for annotated plasmid-specific genes in the genetic
environment of contigs that harboured the blaVIM gene.
Additional laboratory experiments, e.g. plasmid prepara-
tions and transconjugation experiments, might potentially
provide further insights. However, these experimental set-
tings are hampered by the fact, that bacterial isolates can
contain multiple plasmids of various sizes [47], making it
nearly impossible to interpret the data in terms of ARG
localisation, especially in studies including many distinct
isolates. Moreover, even in the case of an observed trans-
fer in transconjugation experiments, it can be tricky to
infer the direction of an ARG transmission as it has oc-
curred beyond laboratory standardization in a clinical set-
ting. Considering these limitations, we are still confident
that the application of our multistep-analysis approach
based on WGS data did produce a comprehensive over-
view of the ARGs and predicted plasmids in our study
isolates.
Conclusions
Based on the findings presented above, there is no
evidence for a horizontal gene transfer of ARGs on
transposons or plasmids from members of the P.
putida group to P. aeruginosa in our hospital. Al-
though ARG transfer might have occurred below our
detection limit, the transfer of ARGs into a P. aerugi-
nosa strain that is successfully adapted to surviving in
the hospital environment and that is capable of col-
onizing patients seems to be a rare event and was
not observed during the study period of 28 months
including a total of 21,373 active screening cultures.
Nevertheless, further studies need to be conducted to
understand the mechanisms and to monitor the oc-
currence of horizontal gene transfer, not only between
species of the same genus but also between more dis-
tinct bacterial taxa, particularly between Pseudomonas
sp. and the clinically relevant Enterobacteriaceae.
While we consider the latter scenario as indeed pos-
sible and a potential event with a severe impact, we
can also state at this point that the isolation of blaVIM
positive Enterobactericeae is still very uncommon in
our hospital, which is the reason why we did not ad-
dress this issue in our study. In summary, based on
the evidence provided here, we do not see the neces-
sity of applying particular infection control measures
for patients colonized with blaVIM positive P. putida
strains in our hospital.
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